Patents by Inventor Hannah Joy Edwards

Hannah Joy Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENZYME INHIBITORS
    Publication number: 20240059691
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, R5, n, Z, X, Y and B are as defined herein. The present invention also relates to compounds useful as synthetic intermediates of compounds of formula (I).
    Type: Application
    Filed: December 1, 2021
    Publication date: February 22, 2024
    Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, William Jack GREVES, Simon Teanby HODGSON, Alessandro MAZZACANI, Carl Leslie NORTH, Alicja Stela OBARA, Michael Bryan ROE, David Philip ROOKER, Michael John STOCKS, Louise Michelle BIRCH, Mark PICHOWICZ, Rachael PITTAWAY, Alun John SMITH, Adam Eric THROUP, Joseph William WRIGGLESWORTH, Xuezheng YANG, David Edward CLARK
  • Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
    Patent number: 11739068
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3 -(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: August 29, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards
  • ENZYME INHIBITORS
    Publication number: 20230250080
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: March 27, 2023
    Publication date: August 10, 2023
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
  • Enzyme inhibitors
    Patent number: 11613527
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 28, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
  • ENZYME INHIBITORS
    Publication number: 20220363668
    Abstract: The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: November 17, 2022
    Inventors: Hannah Joy EDWARDS, David Michael EVANS, Alessandro MAZZACANI, Alicja Stela OBARA, David Edward CLARK, Emanuela GANCIA, Rachael PITTAWAY, Joseph William WRIGGLESWORTH
  • ENZYME INHIBITORS
    Publication number: 20220298138
    Abstract: The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: September 22, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Sally Louise MARSH, Alessandro MAZZACANI, David Philip ROOKER, Michael John STOCKS, Andrew Peter CRIDLAND, Emanuela GANCIA, Julie Nicole HAMBLIN, Paul Stuart HINCHLIFFE, Stefano LEVANTO, Terence Aaron PANCHAL, Iain Robert MILLER
  • ENZYME INHIBITORS
    Publication number: 20220298141
    Abstract: The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.
    Type: Application
    Filed: August 21, 2019
    Publication date: September 22, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Andrew Peter CRIDLAND, Emanuela GANCIA, Erica Lee GOLDSMITH, Paul Stuart HINCHLIFFE, Karamjit Singh JANDU, Alun John SMITH
  • N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors
    Publication number: 20220289729
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 15, 2022
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • ENZYME INHIBITORS
    Publication number: 20220289727
    Abstract: The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 15, 2022
    Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, David Edward CLARK, Paul Stuart HINCHLIFFE, Thomas Matthew BAKER, Colin Peter SAMBROOK SMITH, Alun John SMITH, Joseph William WRIGGLESWORTH, Xuezheng YANG
  • Inhibitors Of Plasma Kallikrein
    Publication number: 20220153724
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • ENZYME INHIBITORS
    Publication number: 20220048894
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 17, 2022
    Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
  • POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF
    Publication number: 20220041571
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 10, 2022
    Inventors: Haydn BEATON, David Malcolm CROWE, Hannah Joy EDWARDS
  • Inhibitors of plasma kallikrein
    Patent number: 11242333
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 8, 2022
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
    Patent number: 11230537
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 25, 2022
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards, Nicholas James Griffiths-Haynes
  • ENZYME INHIBITORS
    Publication number: 20220002275
    Abstract: The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 6, 2022
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
  • N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
    Patent number: 11198691
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: December 14, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
    Patent number: 11084809
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: August 10, 2021
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
    Patent number: 11001578
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: May 11, 2021
    Assignee: KALVISTA PHARMACEUTICALS LIMITED
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors
    Publication number: 20200361923
    Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 19, 2020
    Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
  • POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AS IALLIKREIN INHIBITORS
    Publication number: 20200317633
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy
    Type: Application
    Filed: June 1, 2017
    Publication date: October 8, 2020
    Inventors: Haydn BEATON, David Malcolm CROWE, Hannah Joy EDWARDS, Nicholas James GRIFFITHS-HAYNES